) recently announced that it has enrolled the first patient in a
phase II study of BL-8040, for the treatment of acute myeloid
We remind investors that in Sep 2012, the rights to BL-8040
were in-licensed by the company from Biokine Therapeutics Ltd.
BioLineRx is looking to develop BL-8040 for the treatment of AML
and other types of hematological cancers.
The multicenter, open-label phase II study will evaluate the
safety and efficacy of repeated escalating doses of BL-8040 in
adults suffering from relapsed/refractory AML. Primary endpoints
include safety and tolerability of BL-8040. Secondary endpoints
include the pharmacokinetic profile of the candidate and an
BioLineRx will also assess the capabilities of BL-8040 in
mobilizing cancer cells from the bone marrow to the peripheral
blood, and in inducing their cell death. Roughly 50 patients will
be enrolled across 8 sites in the US and Israel. BioLineRx
expects partial results in the fourth quarter of 2013.
As per BioLineRx, approximately 250,000 adults worldwide are
diagnosed with AML every year. In spite of efforts being made to
develop therapies for AML, less than 25% of patients survive 5
years after being diagnosed with the disease.
Currently available treatments include chemotherapy, radiation
therapy and stem cell transplantation.
Some of the candidates developed by BioLineRx include BL-5010
for the treatment of skin lesions, BL-7040 for the treatment of
inflammatory bowel disease and BL-1021 for the treatment of
currently carries a Zacks Rank #3 (Hold).Currently, companies
Salix Pharmaceuticals Ltd.
) look well positioned with a Zacks Rank #1 (Strong Buy).
BIOLINE RX LTD (BLRX): Get Free Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
To read this article on Zacks.com click here.